Edward Portnay, MD
Interventional Cardiology · Stamford, CTNPI 1093810590
Payments from drug & device makers
Across 274 payments — averaging $7860.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$901K
- Amgen$539K
- Eli Lilly$474K
- AstraZeneca$137K
- Abbott$65K
- Esperion Therapeutics, Inc.$21K
- plus $18K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $900,904 |
| Amgen | 60 | $538,590 |
| Eli Lilly | 2 | $473,744 |
| AstraZeneca | 28 | $136,830 |
| Abbott | 30 | $64,552 |
| Esperion Therapeutics, Inc. | 31 | $21,256 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Bayer | 4 | $4,615 |
| Boehringer Ingelheim | 10 | $4,444 |
| Boehringer Ingelheim International GmbH | 7 | $672 |
| Johnson & Johnson | 13 | $221 |
| Sanofi-aventis U.S. LLC | 8 | $186 |
| Regeneron Healthcare Solutions, Inc. | 7 | $162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $133 |
| Boston Scientific | 3 | $124 |
| Pfizer | 4 | $72 |
| Amarin Pharma, Inc. | 3 | $61 |
| Medtronic | 1 | $58 |
| Edwards Lifesciences | 2 | $57 |
| Scpharmaceuticals Inc. | 3 | $57 |
| Gilead | 3 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $37 |
| Bridgebio Pharma, Inc. | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Cvrx, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Biotronik Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Preventice Services, LLC | 1 | $17 |
| Abiomed | 1 | $16 |
How this compares
$2,153,711 in reported general payments places this provider in the 95th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Stamford
- Arzhang FallahiStamford$12K
- Nicola CorvajaStamford$5K
- Hari DeshpandeNew Haven$1.2M
- Hal WassermanDanbury$848K
- Craig ThompsonHartford$682K
- Samit ShahNew Haven$584K
- Amit VoraNew Haven$530K
- Joseph IngrassiaHartford$387K
- Jawad HaiderBloomfield$373K
- Robert AttaranBridgeport$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.